Pub Date : 2022-01-01Epub Date: 2022-09-06DOI: 10.5173/ceju.2022.0143
Wies Vanderbruggen, Marc Claessens, Vincent De Coninck, Aline Duchateau, Thomas Gevaert, Steven Joniau, Robert Hente
Introduction: Collecting duct, or Bellini duct, renal cell carcinoma (CDRCC) is a rare tumour, comprising only 0.4-2% of all renal cell carcinoma. The goal of this study was to evaluate the cases in our institution and look at current available literature.
Material and methods: We searched all data on renal cell tumours in our institution between 2011 and 2021 and identified four cases with confirmed CDRCC pathology. Important features were listed and analysed. We also reviewed current available literature and compared it to our case series.
Results: All cases were men with a median age of 63.5 years. All were symptomatic at presentation. Two patients presented with flank pain and two with gross haematuria. Three patients had stage IV disease at time of presentation and one stage III disease. All cases had clear Bellini duct renal cell carcinoma appearance on microscopy with infiltrative tubular architecture and high-grade nuclear features. Immunohistochemic (IHC) staining was performed for diagnostic confirmation. Three patients underwent radical nephrectomy and received adjuvant chemotherapy. One case had kidney biopsy for diagnostic confirmation and received first line chemotherapy. Immunotherapy or tyrosine kinase inhibitor (TKI) were started for second, third or fourth line of treatment. Median overall survival after diagnosis was 11 months.
Conclusions: CDRCC is a rare subtype of renal cell carcinoma with poor prognosis, typically presenting in a more advanced or metastatic stage. Diagnosis can be challenging. Multimodality treatment should be considered using radical surgery and systemic treatment.
{"title":"Collecting duct renal cell carcinoma: a single centre series and review of the literature.","authors":"Wies Vanderbruggen, Marc Claessens, Vincent De Coninck, Aline Duchateau, Thomas Gevaert, Steven Joniau, Robert Hente","doi":"10.5173/ceju.2022.0143","DOIUrl":"https://doi.org/10.5173/ceju.2022.0143","url":null,"abstract":"<p><strong>Introduction: </strong>Collecting duct, or Bellini duct, renal cell carcinoma (CDRCC) is a rare tumour, comprising only 0.4-2% of all renal cell carcinoma. The goal of this study was to evaluate the cases in our institution and look at current available literature.</p><p><strong>Material and methods: </strong>We searched all data on renal cell tumours in our institution between 2011 and 2021 and identified four cases with confirmed CDRCC pathology. Important features were listed and analysed. We also reviewed current available literature and compared it to our case series.</p><p><strong>Results: </strong>All cases were men with a median age of 63.5 years. All were symptomatic at presentation. Two patients presented with flank pain and two with gross haematuria. Three patients had stage IV disease at time of presentation and one stage III disease. All cases had clear Bellini duct renal cell carcinoma appearance on microscopy with infiltrative tubular architecture and high-grade nuclear features. Immunohistochemic (IHC) staining was performed for diagnostic confirmation. Three patients underwent radical nephrectomy and received adjuvant chemotherapy. One case had kidney biopsy for diagnostic confirmation and received first line chemotherapy. Immunotherapy or tyrosine kinase inhibitor (TKI) were started for second, third or fourth line of treatment. Median overall survival after diagnosis was 11 months.</p><p><strong>Conclusions: </strong>CDRCC is a rare subtype of renal cell carcinoma with poor prognosis, typically presenting in a more advanced or metastatic stage. Diagnosis can be challenging. Multimodality treatment should be considered using radical surgery and systemic treatment.</p>","PeriodicalId":9744,"journal":{"name":"Central European Journal of Urology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ac/f2/CEJU-75-0143.PMC9628731.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40476440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Open radical nephroureterectomy (ONU) is the standard of care for treatment of upper tract urothelial carcinoma (UTUC), but laparoscopic radical nephroureterectomy (LNU) is increasingly being used due to better perioperative outcomes. However, its oncological safety remains controversial, in particular for advanced disease.We aimed to compare perioperative and oncological outcomes between surgical approaches in locally advanced UTUC (≥pT3 and/or pN+).
Material and methods: This study was a retrospective analysis of all 48 patients submitted to radical nephroureterectomy for advanced UTUC between 2006 and 2020 in our center.Perioperative data were compared between groups. Bladder tumor-free survival (BTFS), metastasis-free survival (MFS) and cancer-specific survival (CSS) were estimated using Kaplan-Meier curves and compared with log-rank p test. Multivariable Cox regression model was used to evaluate their association with surgical approach.
Results: Clinical and pathological characteristics were similar between groups. LNU had lower blood loss (p = 0.031), need for transfusion (p = 0.013) and length of hospital stay (p <0.001), with similar operative time (p = 0.860).LNU was associated with better MFS (hazard ratio [HR]: 0.43, 95% confidence interval [CI] 0.20-0.93, p = 0.033) and CSS (HR: 0.42, 95%CI 0.19-0.94, p = 0.036). Median time to cancer death was 41 months for LNU and 12 months for ONU (log-rank p = 0.029). BTFS was similar between groups (HR: 0.60, 95%CI 0.17-2.11, p = 0.427). On multivariable Cox regression model, surgical approach wasn't significantly associated with MFS (p = 0.202), CSS (p = 0.149) or BTFS (p = 0.586).
Conclusions: In our cohort of advanced UTUC, LNU did not result in inferior oncological control compared to ONU. The minimally invasive approach conferred an advantage in perioperative outcomes.
{"title":"Perioperative and oncological outcomes of laparoscopic and open radical nephroureterectomy for locally advanced upper tract urothelial carcinoma: a single-center cohort study.","authors":"Jorge Correia, Gonçalo Mendes, Bernardo Texeira, Mariana Madanelo, Avelino Fraga, Miguel Silva-Ramos","doi":"10.5173/ceju.2022.103","DOIUrl":"https://doi.org/10.5173/ceju.2022.103","url":null,"abstract":"<p><strong>Introduction: </strong>Open radical nephroureterectomy (ONU) is the standard of care for treatment of upper tract urothelial carcinoma (UTUC), but laparoscopic radical nephroureterectomy (LNU) is increasingly being used due to better perioperative outcomes. However, its oncological safety remains controversial, in particular for advanced disease.We aimed to compare perioperative and oncological outcomes between surgical approaches in locally advanced UTUC (≥pT3 and/or pN+).</p><p><strong>Material and methods: </strong>This study was a retrospective analysis of all 48 patients submitted to radical nephroureterectomy for advanced UTUC between 2006 and 2020 in our center.Perioperative data were compared between groups. Bladder tumor-free survival (BTFS), metastasis-free survival (MFS) and cancer-specific survival (CSS) were estimated using Kaplan-Meier curves and compared with log-rank p test. Multivariable Cox regression model was used to evaluate their association with surgical approach.</p><p><strong>Results: </strong>Clinical and pathological characteristics were similar between groups. LNU had lower blood loss (p = 0.031), need for transfusion (p = 0.013) and length of hospital stay (p <0.001), with similar operative time (p = 0.860).LNU was associated with better MFS (hazard ratio [HR]: 0.43, 95% confidence interval [CI] 0.20-0.93, p = 0.033) and CSS (HR: 0.42, 95%CI 0.19-0.94, p = 0.036). Median time to cancer death was 41 months for LNU and 12 months for ONU (log-rank p = 0.029). BTFS was similar between groups (HR: 0.60, 95%CI 0.17-2.11, p = 0.427). On multivariable Cox regression model, surgical approach wasn't significantly associated with MFS (p = 0.202), CSS (p = 0.149) or BTFS (p = 0.586).</p><p><strong>Conclusions: </strong>In our cohort of advanced UTUC, LNU did not result in inferior oncological control compared to ONU. The minimally invasive approach conferred an advantage in perioperative outcomes.</p>","PeriodicalId":9744,"journal":{"name":"Central European Journal of Urology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a5/b8/CEJU-75-0103.PMC9628717.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40476445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01Epub Date: 2022-05-04DOI: 10.5173/ceju.2022.0284
Angelo Porreca, Luca Di Gianfrancesco, Walter Artibani, Gian Maria Busetto, Giuseppe Carrieri, Alessandro Antonelli, Lorenzo Bianchi, Eugenio Brunocilla, Aldo Massimo Bocciardi, Marco Carini, Antonio Celia, Giovanni Cochetti, Andrea Gallina, Ettore Mearini, Andrea Minervini, Riccardo Schiavina, Sergio Serni, Daniele D'Agostino, Erica Debbi, Paolo Corsi, Alessandro Crestani
Introduction: The Italian Radical Cystectomy Registry (Registro Italiano Cistectomie - RIC) aimed to analyse outcomes of a multicenter series of patients treated with radical cystectomy (RC) for bladder cancer.
Material and methods: An observational, prospective, multicenter, cohort study was performed to collect data from RC and urinary diversion via open (ORC), laparoscopic (LRC), or robotic-assisted (RARC) techniques performed in 28 Italian Urological Departments. The enrolment was planned from January 2017 to June 2020 (goal: 1000 patients), with a total of 1425 patients included. Chi-square and t-tests were used for categorical and continuous variables. All tests were 2-sided, with a significance level set at p <0.05.
Results: Overall median operative-time was longer in RARCs (390 minutes, IQR 335-465) than ORCs (250, 217-309) and LRCs (292, 228-350) (p <0.001). Lymph node dissection (LND) was performed more frequently in RARCs (97.1%) and LRCs (93.5%) than ORCs (85.6%) (p <0.001), with extended-LND performed 2-fold more frequently in RARCs (61.6%) (p <0.001). The neobladder rate was significantly higher (more than one-half) in RARCs. The median estimated blood loss (EBL) rate was lower in RARCs (250 ml, 165-400) than LRCs (330, 200-600) and ORCs (400, 250-600) (p <0.001), with intraoperative blood transfusion rates of 11.4%, 21.7% and 35.6%, respectively (p <0.001). The conversion to open rate was slightly higher in RARCs (6.8%) than LRCs (4.3%). Intraoperative complications occurred in 1.3% of cases without statistically significant differences among the approaches.
Conclusions: Data from the RIC confirmed the need to collect as much data as possible in a multicenter manner. RARCs proves to be feasible with perioperative complication rates that do not differ from the other approaches.
简介:意大利根治性膀胱切除术登记(Registro Italiano Cistectomie - RIC)旨在分析多中心系列接受根治性膀胱切除术(RC)治疗膀胱癌的患者的结果。材料和方法:一项观察性、前瞻性、多中心、队列研究收集了意大利28个泌尿科通过开放(ORC)、腹腔镜(LRC)或机器人辅助(RARC)技术进行的RC和尿转移的数据。计划于2017年1月至2020年6月入组(目标:1000例患者),共纳入1425例患者。分类变量和连续变量采用卡方检验和t检验。结果:rarc的总中位手术时间(390分钟,IQR 335-465)比ORCs(250、217-309)和lrc(292、228-350)更长(p)。结论:RIC的数据证实了以多中心方式收集尽可能多的数据的必要性。rarc被证明是可行的,其围手术期并发症发生率与其他方法没有什么不同。
{"title":"Robotic-assisted, laparoscopic, and open radical cystectomy: surgical data of 1400 patients from The Italian Radical Cystectomy Registry on intraoperative outcomes.","authors":"Angelo Porreca, Luca Di Gianfrancesco, Walter Artibani, Gian Maria Busetto, Giuseppe Carrieri, Alessandro Antonelli, Lorenzo Bianchi, Eugenio Brunocilla, Aldo Massimo Bocciardi, Marco Carini, Antonio Celia, Giovanni Cochetti, Andrea Gallina, Ettore Mearini, Andrea Minervini, Riccardo Schiavina, Sergio Serni, Daniele D'Agostino, Erica Debbi, Paolo Corsi, Alessandro Crestani","doi":"10.5173/ceju.2022.0284","DOIUrl":"https://doi.org/10.5173/ceju.2022.0284","url":null,"abstract":"<p><strong>Introduction: </strong>The Italian Radical Cystectomy Registry (Registro Italiano Cistectomie - RIC) aimed to analyse outcomes of a multicenter series of patients treated with radical cystectomy (RC) for bladder cancer.</p><p><strong>Material and methods: </strong>An observational, prospective, multicenter, cohort study was performed to collect data from RC and urinary diversion via open (ORC), laparoscopic (LRC), or robotic-assisted (RARC) techniques performed in 28 Italian Urological Departments. The enrolment was planned from January 2017 to June 2020 (goal: 1000 patients), with a total of 1425 patients included. Chi-square and t-tests were used for categorical and continuous variables. All tests were 2-sided, with a significance level set at p <0.05.</p><p><strong>Results: </strong>Overall median operative-time was longer in RARCs (390 minutes, IQR 335-465) than ORCs (250, 217-309) and LRCs (292, 228-350) (p <0.001). Lymph node dissection (LND) was performed more frequently in RARCs (97.1%) and LRCs (93.5%) than ORCs (85.6%) (p <0.001), with extended-LND performed 2-fold more frequently in RARCs (61.6%) (p <0.001). The neobladder rate was significantly higher (more than one-half) in RARCs. The median estimated blood loss (EBL) rate was lower in RARCs (250 ml, 165-400) than LRCs (330, 200-600) and ORCs (400, 250-600) (p <0.001), with intraoperative blood transfusion rates of 11.4%, 21.7% and 35.6%, respectively (p <0.001). The conversion to open rate was slightly higher in RARCs (6.8%) than LRCs (4.3%). Intraoperative complications occurred in 1.3% of cases without statistically significant differences among the approaches.</p><p><strong>Conclusions: </strong>Data from the RIC confirmed the need to collect as much data as possible in a multicenter manner. RARCs proves to be feasible with perioperative complication rates that do not differ from the other approaches.</p>","PeriodicalId":9744,"journal":{"name":"Central European Journal of Urology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c1/34/CEJU-75-0284.PMC9326698.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40608688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01Epub Date: 2022-07-18DOI: 10.5173/ceju.2022.0053
Rocco Simone Flammia, Francesco Chierigo, Christoph Würnschimmel, Mike Wenzel, Benedikt Horlemann, Zhen Tian, Marco Borghesi, Costantino Leonardo, Derya Tilki, Shahrokh F Shariat, Umberto Anceschi, Felix K H Chun, Carlo Terrone, Fred Saad, Michele Gallucci, Pierre I Karakiewicz
Introduction: Non-urothelial variant histology (VH), non-muscle invasive bladder cancer (NMIBC) has received little attention in contemporary urologic literature. Specifically, the effect of female sex on stage at presentation, as well as on cancer-specific mortality (CSM) have not been previously examined in VH NMIBC. Our aim was to test the effect of female sex on stage at presentation and CSM in VH NMIBC.
Material and methods: Within the Surveillance, Epidemiology, and End Results (SEER) database (2004-2016), we identified patients aged ≥18 years, with histologically confirmed VH NMIBC. Logistic regression models addressed T1 stage at diagnosis after multivariable adjustments for tumor grade, age and race/ethnicity. Before Kaplan-Meier plots and Cox regression analyses, propensity score matched adjusting for histological variants, T-stage, tumor grade, age and race/ethnicity was performed.
Results: Overall, 2,205 VH NMIBC patients were identified. Of those, 28% (n = 607) were female. Females were older (77 vs 74 years, p <0.001) and more frequently harbored T1 stage (55 vs 45%, p <0.001). Female sex independently predicted T1 stage (odds ratio [OR] = 1.66, 95% Confidence Interval [CI] = 1.35-2.03, p <0.001). Female sex also exhibited higher CSM, after matching for all assessable variables, including stage (hazard ratio [HR] = 1.91, 95% CI = 1.45-2.54, p <0.001).
Conclusions: In VH NMIBC, female sex is an indicator of higher rate of T1 stage and, fully independently of stage, female sex also results in higher CSM.
{"title":"Sex-related differences in non-urothelial variant histology, non-muscle invasive bladder cancer.","authors":"Rocco Simone Flammia, Francesco Chierigo, Christoph Würnschimmel, Mike Wenzel, Benedikt Horlemann, Zhen Tian, Marco Borghesi, Costantino Leonardo, Derya Tilki, Shahrokh F Shariat, Umberto Anceschi, Felix K H Chun, Carlo Terrone, Fred Saad, Michele Gallucci, Pierre I Karakiewicz","doi":"10.5173/ceju.2022.0053","DOIUrl":"https://doi.org/10.5173/ceju.2022.0053","url":null,"abstract":"<p><strong>Introduction: </strong>Non-urothelial variant histology (VH), non-muscle invasive bladder cancer (NMIBC) has received little attention in contemporary urologic literature. Specifically, the effect of female sex on stage at presentation, as well as on cancer-specific mortality (CSM) have not been previously examined in VH NMIBC. Our aim was to test the effect of female sex on stage at presentation and CSM in VH NMIBC.</p><p><strong>Material and methods: </strong>Within the Surveillance, Epidemiology, and End Results (SEER) database (2004-2016), we identified patients aged ≥18 years, with histologically confirmed VH NMIBC. Logistic regression models addressed T1 stage at diagnosis after multivariable adjustments for tumor grade, age and race/ethnicity. Before Kaplan-Meier plots and Cox regression analyses, propensity score matched adjusting for histological variants, T-stage, tumor grade, age and race/ethnicity was performed.</p><p><strong>Results: </strong>Overall, 2,205 VH NMIBC patients were identified. Of those, 28% (n = 607) were female. Females were older (77 vs 74 years, p <0.001) and more frequently harbored T1 stage (55 vs 45%, p <0.001). Female sex independently predicted T1 stage (odds ratio [OR] = 1.66, 95% Confidence Interval [CI] = 1.35-2.03, p <0.001). Female sex also exhibited higher CSM, after matching for all assessable variables, including stage (hazard ratio [HR] = 1.91, 95% CI = 1.45-2.54, p <0.001).</p><p><strong>Conclusions: </strong>In VH NMIBC, female sex is an indicator of higher rate of T1 stage and, fully independently of stage, female sex also results in higher CSM.</p>","PeriodicalId":9744,"journal":{"name":"Central European Journal of Urology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/35/20/CEJU-75-0053.PMC9628729.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40476438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01Epub Date: 2022-09-24DOI: 10.5173/ceju.2022.125
Inés Laso-García, Fernando Arias-Fúnez, Marta Santiago-González, Enrique Sanz-Mayayo, Gema Duque-Ruiz, Manuel Hevia-Palacios, Victoria Gómez-Dos-Santos, Andreina Olavarria-Delgado, Ana Palomera-Rico, Francisco Javier Burgos-Revilla
Introduction: The aim of this article was to evaluate the oncological results and safety of cryotherapy for the treatment of renal tumors.
Material and methods: This study was a prospective review and follow-up of patients who underwent cryotherapy from January 2008 to May 2021. Cryotherapy was offered to patients with bilateral tumors, tumors in solitary kidneys, or comorbid patients. Follow-up consisted of a computed tomography (CT) scan and contrast-enhanced ultrasound (CEUS), with analysis of concordance (kappa index). Overall survival and kidney survival were analyzed (Kaplan-Meier).
Results: Cryotherapy was performed 71 times in 67 patients. A total of 74.6% of patients were men. The mean age of patients was 69.7 years (standard deviation (SD) 11.3]. Mean follow-up was 52.7 months (SD 36.2). Mean tumor size was 26.2 mm (SD 7.6). 90% were cT1a, 10% cT1b stage. Type of access was open in 1 patient, laparoscopic in 8, percutaneous US-guided in 8 and percutaneous CT-guided in 54 patients. Biopsy was taken in 60 patients (84.5%) and consisted of renal cell carcinoma (22), oncocytoma (9), papillary carcinoma (4), angiomyolipoma (1), sarcoma (1), and non-conclusive (23).There were 22 complications such as pain in 2 patients, hematoma in 8 and 2 cases of bleeding, all resolved conservatively except for one case of bleeding which required embolization.Recurrences occurred in 16 cases (22.5%). Management was cryotherapy in 25%, radical nephrectomy in 31.3% and surveillance in 43.8%. Concordance between contrast-enhanced ultrasound and CT was 0.8 (excellent).Mean glomerular filtration did not change. One patient developed metastasis.No cancer-specific mortality was found. Overall survival at 12, 24 and 48 months was 98.5%, 96.8% and 76.9% respectively. Kidney survival at 12, 24 and 48 months was 97%, 93.5% and 93.5% respectively.
Conclusions: Cryotherapy for renal tumors is a safe treatment for comorbid or solitary kidney patients, with rare major complications and good oncological outcome.
导读:本文的目的是评价冷冻治疗肾肿瘤的肿瘤学结果和安全性。材料和方法:本研究对2008年1月至2021年5月接受冷冻治疗的患者进行前瞻性回顾和随访。冷冻疗法适用于双侧肿瘤、单侧肾脏肿瘤或合并症患者。随访包括计算机断层扫描(CT)和超声造影(CEUS),并分析一致性(kappa指数)。分析总生存期和肾生存期(Kaplan-Meier)。结果:67例患者共行冷冻治疗71次。74.6%的患者为男性。患者平均年龄为69.7岁(标准差为11.3)。平均随访52.7个月(SD 36.2)。平均肿瘤大小26.2 mm (SD 7.6)。90%为cT1a期,10%为cT1b期。开放方式1例,腹腔镜8例,经皮us引导8例,经皮ct引导54例。60例(84.5%)患者进行了活检,包括肾细胞癌(22例)、嗜瘤细胞瘤(9例)、乳头状癌(4例)、血管平滑肌脂肪瘤(1例)、肉瘤(1例)和不确定(23例)。术后出现疼痛2例,血肿8例,出血2例等22例并发症,除1例出血需栓塞外,其余均保守解决。复发16例(22.5%)。治疗方法为冷冻治疗占25%,根治性肾切除术占31.3%,监测占43.8%。超声造影与CT的符合率为0.8(优秀)。平均肾小球滤过没有改变。1例患者出现转移。没有发现癌症特异性死亡率。12、24和48个月的总生存率分别为98.5%、96.8%和76.9%。12个月、24个月和48个月肾脏存活率分别为97%、93.5%和93.5%。结论:肾肿瘤冷冻治疗对于合并症或单纯性肾患者是一种安全的治疗方法,主要并发症罕见,肿瘤预后良好。
{"title":"Prospective long-term experience in the treatment of renal tumors with cryotherapy: follow-up with computed tomography scan and contrast-enhanced ultrasound.","authors":"Inés Laso-García, Fernando Arias-Fúnez, Marta Santiago-González, Enrique Sanz-Mayayo, Gema Duque-Ruiz, Manuel Hevia-Palacios, Victoria Gómez-Dos-Santos, Andreina Olavarria-Delgado, Ana Palomera-Rico, Francisco Javier Burgos-Revilla","doi":"10.5173/ceju.2022.125","DOIUrl":"https://doi.org/10.5173/ceju.2022.125","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of this article was to evaluate the oncological results and safety of cryotherapy for the treatment of renal tumors.</p><p><strong>Material and methods: </strong>This study was a prospective review and follow-up of patients who underwent cryotherapy from January 2008 to May 2021. Cryotherapy was offered to patients with bilateral tumors, tumors in solitary kidneys, or comorbid patients. Follow-up consisted of a computed tomography (CT) scan and contrast-enhanced ultrasound (CEUS), with analysis of concordance (kappa index). Overall survival and kidney survival were analyzed (Kaplan-Meier).</p><p><strong>Results: </strong>Cryotherapy was performed 71 times in 67 patients. A total of 74.6% of patients were men. The mean age of patients was 69.7 years (standard deviation (SD) 11.3]. Mean follow-up was 52.7 months (SD 36.2). Mean tumor size was 26.2 mm (SD 7.6). 90% were cT1a, 10% cT1b stage. Type of access was open in 1 patient, laparoscopic in 8, percutaneous US-guided in 8 and percutaneous CT-guided in 54 patients. Biopsy was taken in 60 patients (84.5%) and consisted of renal cell carcinoma (22), oncocytoma (9), papillary carcinoma (4), angiomyolipoma (1), sarcoma (1), and non-conclusive (23).There were 22 complications such as pain in 2 patients, hematoma in 8 and 2 cases of bleeding, all resolved conservatively except for one case of bleeding which required embolization.Recurrences occurred in 16 cases (22.5%). Management was cryotherapy in 25%, radical nephrectomy in 31.3% and surveillance in 43.8%. Concordance between contrast-enhanced ultrasound and CT was 0.8 (excellent).Mean glomerular filtration did not change. One patient developed metastasis.No cancer-specific mortality was found. Overall survival at 12, 24 and 48 months was 98.5%, 96.8% and 76.9% respectively. Kidney survival at 12, 24 and 48 months was 97%, 93.5% and 93.5% respectively.</p><p><strong>Conclusions: </strong>Cryotherapy for renal tumors is a safe treatment for comorbid or solitary kidney patients, with rare major complications and good oncological outcome.</p>","PeriodicalId":9744,"journal":{"name":"Central European Journal of Urology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8a/c6/CEJU-75-0125.PMC9628719.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40476443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01Epub Date: 2022-08-18DOI: 10.5173/ceju.2022.0115
Senol Tonyali, Esteban Emiliani, Tarik Emre Şener, Amelia Pietropaolo, Mehmet Ӧzsoy, Omar Aboumarzouk, Bhaskar Somani, Panagiotis Kallidonis, Vincent M J De Coninck, Michele Talso, Etienne Xavier Keller, Nicola Macchione, Thomas Tailly
Introduction: The aim of this article was to evaluate the current perception of urologists as to what size is considered as a clinically insignificant residual fragment (CIRF).
Material and methods: A survey was globally distributed to the members of the Endourological Society via SurveyMonkey.
Results: A total of 385 participants responded to the survey on CIRF. Most participants considered 2 mm (29%) as CIRF threshold, followed by 3 mm (24%), 4 mm (22%), 0 mm (14%), 5 mm (8%) and 1 mm (3%). North American urologists considered CIRF to be smaller than urologists from Asia, Eurasia and South America, (p-values ≤0.001, 0.037 and 0.015 respectively). European urologists identified smaller CIRF in comparison to Asian urologists (p-value = 0.001). Urologists mainly using a pneumatic lithotripter accepted larger fragments as CIRF, compared to urologists mainly using ultrasonic devices or a combination of ultrasonic and pneumatic devices (p-value = 0.026 and 0.005 respectively). Similarly, urologists mainly performing X-Ray and ultrasound as post-operative imaging accepted larger fragments as CIRF in comparison to urologists mainly performing non-contrast computed tomography (p-value = 0.001).
Conclusions: What is considered as CIRF varies between urologist from different continents and seems to be associated with the lithotripter used and the post-operative imaging modality of preference to assess treatment success.
{"title":"Definition of clinically insignificant residual fragments after percutaneous nephrolithotomy among urologists: a world-wide survey by EAU-YAU Endourology and Urolithiasis Working Group.","authors":"Senol Tonyali, Esteban Emiliani, Tarik Emre Şener, Amelia Pietropaolo, Mehmet Ӧzsoy, Omar Aboumarzouk, Bhaskar Somani, Panagiotis Kallidonis, Vincent M J De Coninck, Michele Talso, Etienne Xavier Keller, Nicola Macchione, Thomas Tailly","doi":"10.5173/ceju.2022.0115","DOIUrl":"https://doi.org/10.5173/ceju.2022.0115","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of this article was to evaluate the current perception of urologists as to what size is considered as a clinically insignificant residual fragment (CIRF).</p><p><strong>Material and methods: </strong>A survey was globally distributed to the members of the Endourological Society via SurveyMonkey.</p><p><strong>Results: </strong>A total of 385 participants responded to the survey on CIRF. Most participants considered 2 mm (29%) as CIRF threshold, followed by 3 mm (24%), 4 mm (22%), 0 mm (14%), 5 mm (8%) and 1 mm (3%). North American urologists considered CIRF to be smaller than urologists from Asia, Eurasia and South America, (p-values ≤0.001, 0.037 and 0.015 respectively). European urologists identified smaller CIRF in comparison to Asian urologists (p-value = 0.001). Urologists mainly using a pneumatic lithotripter accepted larger fragments as CIRF, compared to urologists mainly using ultrasonic devices or a combination of ultrasonic and pneumatic devices (p-value = 0.026 and 0.005 respectively). Similarly, urologists mainly performing X-Ray and ultrasound as post-operative imaging accepted larger fragments as CIRF in comparison to urologists mainly performing non-contrast computed tomography (p-value = 0.001).</p><p><strong>Conclusions: </strong>What is considered as CIRF varies between urologist from different continents and seems to be associated with the lithotripter used and the post-operative imaging modality of preference to assess treatment success.</p>","PeriodicalId":9744,"journal":{"name":"Central European Journal of Urology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ce/99/CEJU-75-0115.PMC9628728.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40465609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01Epub Date: 2022-05-18DOI: 10.5173/ceju.2022.0086
Emilia Pawłowska-Krajka, Mateusz Bajkowski, Adam Dorobek, Bartosz Hnatowski, Piotr Radziszewski
Introduction: The demographics of men undergoing vasectomy in Poland has not been thoroughly evaluated. The objective of the study is to characterise patients who underwent vasectomy in 2019-2020 in terms of their motivation, the level of acceptance of the method, their social and health status and the way religion influenced their choice.
Material and methods: This is a prospective observational study based on a survey taken before vasectomy. The surveys attached were collected in 2019-2020. A total number of 253 surveys were collected.
Results: A total of 43 men aged between 31 and 40 constituted 56.52% of all patients. Of the patients surveyed, 123 (48.62%) were in their first stable relationship. In total, 230 participants (90.91%) declared no intention of having children. A total of 128 patients surveyed (50.59%) showed no interest in the possibility of adoption, whereas 109 (43.08%) did consider adoption. Most of the patients - 150 (59.29%), had been considering vasectomy for 1-3 years. The most popular contraceptive methods were oral contraception - 68 surveyed (26.88%) and condoms - 66 (26.09%). Vasectomy did not collide with religion in 241 cases (95.26%). Seven patients (2.77%) chose vasectomy due to a genetic defect. A total of 46 out of 243 men (18.18%) chose this contraceptive method due to their partners' health.
Conclusions: Vasectomy in Poland has been performed for over 18 years, however, accessibility has been limited. Recently, the procedure has been gaining in popularity. Now the age structure and partnership status correspond with the data from other centres in the world. Our study showed positive trends of co-responsibility of both partners for procreation and family planning.
{"title":"Demographics of men receiving vasectomies in Poland 2019-2020.","authors":"Emilia Pawłowska-Krajka, Mateusz Bajkowski, Adam Dorobek, Bartosz Hnatowski, Piotr Radziszewski","doi":"10.5173/ceju.2022.0086","DOIUrl":"https://doi.org/10.5173/ceju.2022.0086","url":null,"abstract":"<p><strong>Introduction: </strong>The demographics of men undergoing vasectomy in Poland has not been thoroughly evaluated. The objective of the study is to characterise patients who underwent vasectomy in 2019-2020 in terms of their motivation, the level of acceptance of the method, their social and health status and the way religion influenced their choice.</p><p><strong>Material and methods: </strong>This is a prospective observational study based on a survey taken before vasectomy. The surveys attached were collected in 2019-2020. A total number of 253 surveys were collected.</p><p><strong>Results: </strong>A total of 43 men aged between 31 and 40 constituted 56.52% of all patients. Of the patients surveyed, 123 (48.62%) were in their first stable relationship. In total, 230 participants (90.91%) declared no intention of having children. A total of 128 patients surveyed (50.59%) showed no interest in the possibility of adoption, whereas 109 (43.08%) did consider adoption. Most of the patients - 150 (59.29%), had been considering vasectomy for 1-3 years. The most popular contraceptive methods were oral contraception - 68 surveyed (26.88%) and condoms - 66 (26.09%). Vasectomy did not collide with religion in 241 cases (95.26%). Seven patients (2.77%) chose vasectomy due to a genetic defect. A total of 46 out of 243 men (18.18%) chose this contraceptive method due to their partners' health.</p><p><strong>Conclusions: </strong>Vasectomy in Poland has been performed for over 18 years, however, accessibility has been limited. Recently, the procedure has been gaining in popularity. Now the age structure and partnership status correspond with the data from other centres in the world. Our study showed positive trends of co-responsibility of both partners for procreation and family planning.</p>","PeriodicalId":9744,"journal":{"name":"Central European Journal of Urology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4b/c7/CEJU-75-0086.PMC9326707.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40608687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Recent publications of interstitial cystitis (IC)/bladder pain syndrome cure by a gynecological prolapse protocol, run counter to traditional treatments such as bladder installations which do not offer such cure. The prolapse protocol, uterosacral ligament (USL) repair, is based on the 'Posterior Fornix Syndrome' (PFS). PFS was described in the 1993 iteration of the Integral Theory. PFS comprises predictably co-occurring symptoms of frequency, urgency, nocturia, chronic pelvic pain, abnormal emptying and post-void residual urine, caused by USL laxity and cured or improved by repair thereof.
Material and methods: analysis and interpretation of published data showing cure of IC by USL repair.
Results: In many women, USL pathogenesis of IC can be explained by the effect of weak or loose USLs weakening two pelvic muscles which contract against them, levator plate (LP) and conjoint longitudinal muscle of the anus (LMA). The now weakened pelvic muscles cannot stretch the vagina sufficiently to prevent afferent impulses from urothelial stretch receptors 'N' reaching the micturition centre where they are interpreted as urge. The same unsupported USLs cannot support the visceral sympathetic/parasympathetic visceral autonomic nerve plexuses (VP). The pathway of multiple referred pelvic pains is explained as follows: groups of afferent VP axons stimulated by gravity or muscle movements fire off 'rogue' impulses, which are interpreted by the cortex as end-organ chronic pelvic pain (CPP) from several end organs; this explains how CPP is invariably perceived in several sites. Reports of cure of non-Hunner's and Hunner's IC are analysed with diagrams which explain co-occurrence of IC with urge and phenotypes of chronic pelvic pain from several different sites.
Conclusions: A gynecological schema cannot explain all IC phenotypes, especially male IC. However, for those women who obtain relief from the predictive speculum test, there is a significant possibility of cure of both the pain and the urge by uterosacral ligament repair. In this context, it may well be in such female patients' interests, at least in the exploratory diagnostic phase, for ICS/BPS to be subsumed into the PFS disease category. It would give such women a significant chance of cure, something denied to them for now.
{"title":"A gynecological perspective of interstitial cystitis/bladder pain syndrome may offer cure in selected cases.","authors":"Peter Petros","doi":"10.5173/ceju.2022.106","DOIUrl":"https://doi.org/10.5173/ceju.2022.106","url":null,"abstract":"<p><strong>Introduction: </strong>Recent publications of interstitial cystitis (IC)/bladder pain syndrome cure by a gynecological prolapse protocol, run counter to traditional treatments such as bladder installations which do not offer such cure. The prolapse protocol, uterosacral ligament (USL) repair, is based on the 'Posterior Fornix Syndrome' (PFS). PFS was described in the 1993 iteration of the Integral Theory. PFS comprises predictably co-occurring symptoms of frequency, urgency, nocturia, chronic pelvic pain, abnormal emptying and post-void residual urine, caused by USL laxity and cured or improved by repair thereof.</p><p><strong>Material and methods: </strong>analysis and interpretation of published data showing cure of IC by USL repair.</p><p><strong>Results: </strong>In many women, USL pathogenesis of IC can be explained by the effect of weak or loose USLs weakening two pelvic muscles which contract against them, levator plate (LP) and conjoint longitudinal muscle of the anus (LMA). The now weakened pelvic muscles cannot stretch the vagina sufficiently to prevent afferent impulses from urothelial stretch receptors 'N' reaching the micturition centre where they are interpreted as urge. The same unsupported USLs cannot support the visceral sympathetic/parasympathetic visceral autonomic nerve plexuses (VP). The pathway of multiple referred pelvic pains is explained as follows: groups of afferent VP axons stimulated by gravity or muscle movements fire off 'rogue' impulses, which are interpreted by the cortex as end-organ chronic pelvic pain (CPP) from several end organs; this explains how CPP is invariably perceived in several sites. Reports of cure of non-Hunner's and Hunner's IC are analysed with diagrams which explain co-occurrence of IC with urge and phenotypes of chronic pelvic pain from several different sites.</p><p><strong>Conclusions: </strong>A gynecological schema cannot explain all IC phenotypes, especially male IC. However, for those women who obtain relief from the predictive speculum test, there is a significant possibility of cure of both the pain and the urge by uterosacral ligament repair. In this context, it may well be in such female patients' interests, at least in the exploratory diagnostic phase, for ICS/BPS to be subsumed into the PFS disease category. It would give such women a significant chance of cure, something denied to them for now.</p>","PeriodicalId":9744,"journal":{"name":"Central European Journal of Urology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e2/e3/CEJU-75-106.PMC9903172.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10740121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Carlos A Riveros, Victor Chalfant, Thomas Melchart, Gurjot Singh, Ana M Forero, Braian Ledesma, Susan Harnett, Andrew A Stec, Michael Feloney, Joan C Delto, Dane E Klett
Introduction: Retrograde ureteroscopy with holmium laser lithotripsy (HLL) is a standard treatment for urolithiasis. Moses technology has been shown to improve fragmentation efficiency in vitro; however, it is still unclear how it performs clinically compared to standard HLL. We performed a systematic review and meta-analysis evaluating the differences in efficiency and outcomes between Moses mode and standard HLL.
Material and methods: We searched the MEDLINE, EMBASE, and CENTRAL databases for randomized clinical trials and cohort studies comparing Moses mode and standard HLL in adults with urolithiasis. Outcomes of interest included operative (operation, fragmentation, and lasing times; total energy used; and ablation speed) and perioperative parameters (stone-free rate and overall complication rate).
Results: The search identified six studies eligible for analysis. Compared to standard HLL, Moses was associated with significantly shorter average lasing time (mean difference [MD] -0.95, 95% confidence interval [CI] -1.22 to -0.69 minutes), faster stone ablation speed (MD 30.45, 95% CI 11.56-49.33 mm3/min), and higher energy used (MD 1.04, 95% CI 0.33-1.76 kJ). Moses and standard HLL were not significantly different in terms of operation (MD -9.89, 95% CI -25.14 to 5.37 minutes) and fragmentation times (MD -1.71, 95% CI -11.81 to 8.38 minutes), as well as stone-free (odds ratio [OR] 1.04, 95% CI 0.73-1.49) and overall complication rates (OR 0.68, 95% CI 0.39-1.17).
Conclusions: While perioperative outcomes were equivalent between Moses and standard HLL, Moses was associated with faster lasing time and stone ablation speeds at the expense of higher energy usage.
导读:逆行输尿管镜钬激光碎石术(HLL)是治疗尿石症的标准方法。Moses技术已被证明可以提高体外破碎效率;然而,与标准HLL相比,其临床表现尚不清楚。我们进行了系统回顾和荟萃分析,评估Moses模式和标准HLL之间的效率和结果差异。材料和方法:我们检索了MEDLINE、EMBASE和CENTRAL数据库中比较Moses模式和标准HLL在成人尿石症患者中的随机临床试验和队列研究。关注的结果包括手术(手术、碎片和激光时间);使用的总能源;消融速度)和围手术期参数(结石游离率和总并发症发生率)。结果:检索确定了6项符合分析条件的研究。与标准HLL相比,Moses与较短的平均激光时间(平均差[MD] -0.95, 95%可信区间[CI] -1.22至-0.69分钟)、更快的结石消融速度(MD 30.45, 95% CI 11.56-49.33 mm3/min)和较高的能量消耗(MD 1.04, 95% CI 0.33-1.76 kJ)相关。Moses和标准HLL在手术(MD -9.89, 95% CI -25.14至5.37分钟)、碎裂时间(MD -1.71, 95% CI -11.81至8.38分钟)、无结石(优势比[OR] 1.04, 95% CI 0.73-1.49)和总并发症发生率(OR 0.68, 95% CI 0.39-1.17)方面无显著差异。结论:虽然Moses和标准HLL的围手术期结果相当,但Moses与更快的激光时间和更快的结石消融速度相关,但以更高的能量消耗为代价。
{"title":"Does Moses technology improve the efficiency and outcomes of standard holmium laser lithotripsy? A systematic review and meta-analysis.","authors":"Carlos A Riveros, Victor Chalfant, Thomas Melchart, Gurjot Singh, Ana M Forero, Braian Ledesma, Susan Harnett, Andrew A Stec, Michael Feloney, Joan C Delto, Dane E Klett","doi":"10.5173/ceju.2022.156","DOIUrl":"https://doi.org/10.5173/ceju.2022.156","url":null,"abstract":"<p><strong>Introduction: </strong>Retrograde ureteroscopy with holmium laser lithotripsy (HLL) is a standard treatment for urolithiasis. Moses technology has been shown to improve fragmentation efficiency in vitro; however, it is still unclear how it performs clinically compared to standard HLL. We performed a systematic review and meta-analysis evaluating the differences in efficiency and outcomes between Moses mode and standard HLL.</p><p><strong>Material and methods: </strong>We searched the MEDLINE, EMBASE, and CENTRAL databases for randomized clinical trials and cohort studies comparing Moses mode and standard HLL in adults with urolithiasis. Outcomes of interest included operative (operation, fragmentation, and lasing times; total energy used; and ablation speed) and perioperative parameters (stone-free rate and overall complication rate).</p><p><strong>Results: </strong>The search identified six studies eligible for analysis. Compared to standard HLL, Moses was associated with significantly shorter average lasing time (mean difference [MD] -0.95, 95% confidence interval [CI] -1.22 to -0.69 minutes), faster stone ablation speed (MD 30.45, 95% CI 11.56-49.33 mm<sup>3</sup>/min), and higher energy used (MD 1.04, 95% CI 0.33-1.76 kJ). Moses and standard HLL were not significantly different in terms of operation (MD -9.89, 95% CI -25.14 to 5.37 minutes) and fragmentation times (MD -1.71, 95% CI -11.81 to 8.38 minutes), as well as stone-free (odds ratio [OR] 1.04, 95% CI 0.73-1.49) and overall complication rates (OR 0.68, 95% CI 0.39-1.17).</p><p><strong>Conclusions: </strong>While perioperative outcomes were equivalent between Moses and standard HLL, Moses was associated with faster lasing time and stone ablation speeds at the expense of higher energy usage.</p>","PeriodicalId":9744,"journal":{"name":"Central European Journal of Urology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2f/e9/CEJU-75-156.PMC9903166.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9852041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01Epub Date: 2022-06-22DOI: 10.5173/ceju.2022.0104
Giacomo Maria Pirola, Daniele Castellani, Martina Maggi, Ee Jean Lim, Vinson Wai Shun Chan, Angelo Naselli, Jeremy Yuen Chun Teoh, Vineet Gauhar
Introduction: The aim of this article was to enumerate the differences in immediate and postoperative outcomes for holmium laser enucleation of the prostate (HoLEP) performed with low-power (LP) or high-power (HP) laser settings through a systematic review of comparative studies.
Material and methods: We performed a systematic literature review using MEDLINE, EMBASE, and Cochrane Central Controlled Register of Trials. Potential clinical differences among LP and HP HoLEP were determined using the PICOS (Patient Intervention Comparison Outcome Study type) model, where outcomes were surgical time, operative efficiency, postoperative catheterization time, length of hospital stay, blood transfusion, incontinence rate, maximum urinary flow rate (QMax) and International Prostatic Symptom score (IPSS). Retrospective, prospective nonrandomized, randomized studies, and meeting abstracts were considered.
Results: A total of five studies were included for meta-analysis. No significant differences between LP and HP HoLEP were evidenced in terms of intraoperative variables (surgical time, surgical efficiency); postoperative outcomes (length of stay, length of catheterization); postoperative complications; functional results (IPSS; Qmax). Urinary incontinence rate did not differ between the two groups (OR 0.95, 95% CI 0.362.47, p = 0.91).
Conclusions: The study shows equal outcomes in outcomes from HoLEP performed with LP or HP energy settings. Even if further comparative studies are still needed to increase the level of evidence, those results encourage a further clinical adoption of LP HoLEP.
前言:本文的目的是通过对比较研究的系统回顾,列举低功率(LP)或高功率(HP)激光设置进行钬激光前列腺去核(HoLEP)的即时和术后结果的差异。材料和方法:我们使用MEDLINE、EMBASE和Cochrane Central Controlled Register of Trials进行了系统的文献综述。采用PICOS(患者干预比较结果研究类型)模型确定LP和HP HoLEP的潜在临床差异,其中结果包括手术时间、手术效率、术后置管时间、住院时间、输血、失禁率、最大尿流率(QMax)和国际前列腺症状评分(IPSS)。我们考虑了回顾性、前瞻性、非随机、随机研究和会议摘要。结果:共纳入5项研究进行meta分析。在术中变量(手术时间、手术效率)方面,LP与HP之间无显著差异;术后结果(住院时间、置管时间);术后并发症;功能结果(IPSS;Qmax)。两组尿失禁率无差异(OR 0.95, 95% CI 0.362.47, p = 0.91)。结论:该研究显示,在LP或HP能量设置下进行HoLEP的结果相同。即使还需要进一步的比较研究来增加证据水平,这些结果也鼓励了LP HoLEP的进一步临床应用。
{"title":"Does power setting impact surgical outcomes of holmium laser enucleation of the prostate? A systematic review and meta-analysis.","authors":"Giacomo Maria Pirola, Daniele Castellani, Martina Maggi, Ee Jean Lim, Vinson Wai Shun Chan, Angelo Naselli, Jeremy Yuen Chun Teoh, Vineet Gauhar","doi":"10.5173/ceju.2022.0104","DOIUrl":"https://doi.org/10.5173/ceju.2022.0104","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of this article was to enumerate the differences in immediate and postoperative outcomes for holmium laser enucleation of the prostate (HoLEP) performed with low-power (LP) or high-power (HP) laser settings through a systematic review of comparative studies.</p><p><strong>Material and methods: </strong>We performed a systematic literature review using MEDLINE, EMBASE, and Cochrane Central Controlled Register of Trials. Potential clinical differences among LP and HP HoLEP were determined using the PICOS (Patient Intervention Comparison Outcome Study type) model, where outcomes were surgical time, operative efficiency, postoperative catheterization time, length of hospital stay, blood transfusion, incontinence rate, maximum urinary flow rate (QMax) and International Prostatic Symptom score (IPSS). Retrospective, prospective nonrandomized, randomized studies, and meeting abstracts were considered.</p><p><strong>Results: </strong>A total of five studies were included for meta-analysis. No significant differences between LP and HP HoLEP were evidenced in terms of intraoperative variables (surgical time, surgical efficiency); postoperative outcomes (length of stay, length of catheterization); postoperative complications; functional results (IPSS; Qmax). Urinary incontinence rate did not differ between the two groups (OR 0.95, 95% CI 0.362.47, p = 0.91).</p><p><strong>Conclusions: </strong>The study shows equal outcomes in outcomes from HoLEP performed with LP or HP energy settings. Even if further comparative studies are still needed to increase the level of evidence, those results encourage a further clinical adoption of LP HoLEP.</p>","PeriodicalId":9744,"journal":{"name":"Central European Journal of Urology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/73/f3/CEJU-75-0104.PMC9326704.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40677239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}